A Phase I/II, Randomised, Single-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD9550 Monotherapy and Co-administration of AZD9550 and AZD6234 in Participants Living with Obesity and Overweight with or without Type 2 Diabetes Mellitus
Active, not recruitingCTIS2023-504215-32-00
AstraZeneca ABOverweight and obesity
Start: 2023-09-28Target: 101Updated: 2025-10-15